Could This FDA Approval Boost AbbVie's Stock?
On Dec. 16, the U.S. Food and Drug Administration (FDA) gave AbbVie's (NYSE: ABBV) Vraylar the go-ahead as an adjunctive (add-on) treatment for patients with major depressive disorder (MDD).
What was the clinical data behind the FDA's decision to award Vraylar with its fourth indication? And what could this news mean for the pharmaceutical company's financial future? Let's take a look at the results from Vraylar's phase 3 clinical trial and at the U.S. MDD market to find out.
MDD is a prevalent mental health disorder. It is estimated that 10.4% of Americans experience the condition in any given year, and that the lifetime prevalence in the U.S is 20.6%.
Source Fool.com
